Information for "Canakinumab to scale back destruction associated with heart failure and also respiratory perform in SARSCoV2 connected myocardial harm using heightened inflammation canakinumab within Covid19 heart failure injuries The 3 C study"
From EECH Central
Basic information
| Display title | Canakinumab to scale back destruction associated with heart failure and also respiratory perform in SARSCoV2 connected myocardial harm using heightened inflammation canakinumab within Covid19 heart failure injuries The 3 C study |
| Default sort key | Canakinumab to scale back destruction associated with heart failure and also respiratory perform in SARSCoV2 connected myocardial harm using heightened inflammation canakinumab within Covid19 heart failure injuries The 3 C study |
| Page length (in bytes) | 3,317 |
| Page ID | 1386303 |
| Page content language | English (en) |
| Page content model | wikitext |
| Indexing by robots | Allowed |
| Number of redirects to this page | 0 |
Page protection
| Edit | Allow all users (infinite) |
| Move | Allow all users (infinite) |
Edit history
| Page creator | Bandsecure5 (Talk | contribs) |
| Date of page creation | 11:57, 20 April 2024 |
| Latest editor | Bandsecure5 (Talk | contribs) |
| Date of latest edit | 11:57, 20 April 2024 |
| Total number of edits | 1 |
| Total number of distinct authors | 1 |
| Recent number of edits (within past 90 days) | 1 |
| Recent number of distinct authors | 1 |
